Exacerbations in cystic fibrosis: 2 Prevention

Thorax

Volumn 62, Issue 8, 2007, Pages 723-732

  Bell, Scott C ^a,b   Robinson, Philip J ^c  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; AZITHROMYCIN; BRONCHODILATING AGENT; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; DORNASE ALFA; FLUTICASONE; IBUPROFEN; INFLUENZA VACCINE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISOLONE; PSEUDOMONAS VACCINE; RECOMBINANT ENZYME; RECOMBINANT HUMAN DEOXYRIBONUCLEASE; SALBUTAMOL; SODIUM CHLORIDE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG COST; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; EXERCISE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HOSPITAL CARE; HUMAN; INFLUENZA; LUNG DISEASE; LUNG FIBROSIS; META ANALYSIS; MORTALITY; NUTRITION; PHYSIOTHERAPY; PRIORITY JOURNAL; PSEUDOMONAS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VACCINATION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; COST OF ILLNESS; CYSTIC FIBROSIS; DIETARY SUPPLEMENTS; EXERCISE THERAPY; EXPECTORANTS; HUMANS; PHYSICAL THERAPY MODALITIES; RESPIRATION DISORDERS; VACCINATION;

EID: 34547773123     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.060897     Document Type: Review

References (125)

1. Dodge JA, Lewis PA. Cystic fibrosis is no longer an important cause of childhood death in the UK. Arch Dis Child 2005;90:547.
2. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991;46:881-5.
3. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998;316:1771-5.
4. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-9.
5. Yankaskas JR, Fernald GW. Adult social issues. In: Yankaskas JR, Knowles MR, eds. Cystic fibrosis in adults.Lippincott-Raven Publishers, 1999:465-76.
6. 1 in young adults with cystic fibrosis. Thorax 2006;61:155-7.
7. Xu W, Subbarao P, Corey M. Changing patterns of lung function decline in children with cystic fibrosis (abstract). J Cyst Fibros 2004;3(Suppl 1):S116.
8. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52.
9. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72.
10. Robson M, Abbott J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992;47:684-9.
11. Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med 2005;172:99-104.
12. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72.
13. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2003. Bethesda, Maryland: Cystic Fibrosis Foundation, 2003.
14. Balfour-Lynn I, Walters S, Dezateux C. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2000;(1):CD001915.
15. Bhalla P, Tan A, Smyth R. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 2000;(1):CD001753.
16. Bradley JM, Moran FM, Elborn JS. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med 2006;100:191-201.
17. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 1999;(4):CD000407.
18. Elkins MR, Jones A, van der Schans C. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev 2006;(2):CD003147.
19. Lands LC, Dezateux C, Crighton C. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 1999;(2):CD001505.
20. Main E, Prasad A, van der Schans C. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev 2005;(1):CD002011.
21. Moran F, Bradley J. Non-invasive ventilation for cystic fibrosis. Cochrane Database Syst Rev 2003;(2):CD002769.
22. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;(3):CD001021.
23. Smyth A, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;(3):CDO01912.
24. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004;(2):CD002203.
25. van der Schans C, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev 2000;(2):CD001401.
26. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006;(1):CD004197.
27. Goss CH, Burns JL. Exacerbations in cystic fibrosis: epidemiology and pathogenesis. Thorax 2007;62:360-7.
28. Duijvestijn YC, Brand PL. Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr 1999;88:38-41.
29. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
30. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-20.
31. McCoy K, Hamilton S, Johnson C. Effects of 12 weeks administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996;110:889-95.
32. Shah PL, Conway S, Scott SF, et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration 2001;68:160-4.
33. Robinson M, Regnis JA, Bailey DL, et al. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-9.
34. Wark PAB, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2005;(3):CD001506.
35. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358:1316-21.
36. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
37. Bradley J, Moran F. Physical training for cystic fibrosis. Cochrane Database Syst Rev 2002;(2):CD002768.
38. Reisman JJ, Rivington-Law B, Corey M, et al. Role of conventional physiotherapy in cystic fibrosis. J Pediatr 1988;113:632-6.
39. Homnick DN, White F, de Castro C. Comparison of effects of an intrapulmonary percussive ventilator to standard aerosol and chest physiotherapy in treatment of cystic fibrosis. Pediatr Pulmonol 1995;20:50-5.
40. McIlwaine PM, Wong LT, Peacock D, et al. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr 1997;131:570-4.
41. Schneiderman-Walker J, Pollock SL, Corey M, et al. A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. J Pediatr 2000;136:304-10.
42. Klijn PH, Oudshoorn A, van der Ent CK, et al. Effects of anaerobic training in children with cystic fibrosis: a randomized controlled study. Chest 2004;125:1299-305.
43. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571-2.
44. Cystic Fibrosis Australia. Annual report from the Australian Cystic Fibrosis Data Registry. Cystic fibrosis in Australia. Sydney: Cystic Fibrosis Australia, 2003.
45. Martin B, McKay K, Selvadurai H, et al. Prophylactic oral antibiotics in cystic fibrosis may predispose to Pseudomonas aeruginosa acquistion (abstract). Respirology 2006;11(Suppl 2):A11.
46. Nolan G, Moivor P, Levison H, et al. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr 1982;101:626-30.
47. Loening-Baucke VA, Mischler E, Myers MG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. J Pediatr 1979;95:630-7.
48. Ratjen F, Comes G, Paul K, et al. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001;31:13-6.
49. Chatfield S, Owen G, Ryley HC, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child 1991;66:29-33.
50. Schlesinger E, Muller W, von der Hardt H, et al. Effect of longterm continuous anti-staphylococcal antibiotic treatment in young children with cystic fibrosis (abstract). Proceedings of the 9th International Cystic Fibrosis Congress 1984:4.14.
51. Stutman HR, Lieberman JM, Nussbaum E, et al. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002;140:299-305.
52. Weaver LT, Green MR, Nicholson K, et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994;70:84-9.
53. Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence? Pediatr Pulmonol 2005;40:471-6.
54. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6.
55. Gibson RL, Emerson J, McNamara S, et al. A randomized, controlled trial of inhaled tobramycin in young children with cystic fibrosis (abstract). Pediatr Pulmonol 2002;34(Suppl 24):300.
56. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-9.
57. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-4.
58. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
59. Yang I, Kim ST, Bell SC. Antibiotics in COPD, bronchiectasis, and cystic fibrosis. In: Gibson PG, eds. Evidence-based respiratory medicine. Oxford: Blackwell Publishing, 2005:389-413.
60. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
61. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-6.
62. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998;351:420.
63. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84.
64. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
65. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
66. Saiman L, Mayer-Hamblett N, Campbell P, et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172:1008-12.
67. Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006;61:895-902.
68. Phaff SJ, Tiddens HA, Verbrugh HA, et al. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 2006;57:741-6.
69. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-7.
70. Hoiby N, Koch C. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 1990;45:881-4.
71. Bell SC, Bowerman AR, Davies CA, et al. Nutrition in adults with cystic fibrosis. Clin Nutr 1998;17:211-5.
72. Huang NN, Macri CN, Girone J, et al. Survival of patients with cystic fibrosis. Am J Dis Child 1970;120:289-95.
73. Sharma R, Florea VG, Bolger AP, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001;56:746-50.
74. Zemel BS, Jawad AF, FitzSimmons S, et al. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 2000;137:374-80.
75. Corey M. Modelling survival in cystic fibrosis. Thorax 2001;56:743.
76. Boland MP, Stoski DS, Patrick J. Long-term nutritional rehabilitation in cystic fibrosis. J Pediatr 1986;108:489-90.
77. Levy ID, Durie PR, Pencharz PB, et al. Effects of long-term nutritional rehabilitation on body composition and clinical status in malnourished children and adolescents with cystic fibrosis. J Pediatr 1985;107:225-30.
78. Moore MC, Greene HL, Donald WD, et al. Enteral-tube reeding as adjunct therapy in malnourished patients with cystic fibrosis: a clinical study and literature review. Am J Clin Nutr 1986;44:33-41.
79. Shepherd RW, Holt TL, Cleghorn G, et al. Short-term nutritional supplementation during management of pulmonary exacerbations in cystic fibrosis: a controlled study, including effects of protein turnover. Am J Clin Nutr 1988;48:235-9.
80. Shepherd RW, Thomas BJ, Bennett D, et al. Changes in body composition and muscle protein degradation during nutritional supplementation in nutritionally growth-retarded children with cystic fibrosis. J Pediatr Gastroenterol Nutr 1983;2:439-46.
81. Steinkamp G, Rodeck B, Seidenberg J, et al. [Stabilization of lung function in cystic fibrosis during long-term tube feeding via a percutaneous endoscopic gastrostomy]. Pneumologie 1990;44:1151-3.
82. Poustie VJ, Russell JE, Watling RM, et al. Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial. BMJ 2006;332:632-6.
83. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997;337:963-9.
84. Berger M, Konstan MW. Immunopathogenesis of cystic fibrosis lung disease. In: Yankaskas JR, Knowles MR, eds. Cystic fibrosis in adults. Lippincott-Raven, 1999:115-43.
85. Auerbach HS, Williams M, Kirkpatrick JA, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2:686-8.
86. Eigen H, Rosenstein BJ, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995;126:515-23.
87. Greally P, Hussain MJ, Vergani D, et al. Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 1994;71:35-9.
88. Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006;173:1356-62.
89. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-54.
90. Konstan MW, Hoppel CL, Chai BL, et al. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr 1991;118:956-64.
91. Sodelli DO, Macri CN, Maillie AJ. A preliminary report of the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection. Int J Immunopathol Pharmacol 1994;7:109-17.
92. Fennell PB, Quante J, Wilson K, et al. Use of high-dose ibuprofen in a pediatric cystic fibrosis center. J Cyst Fibros 2007;6:153-8.
93. Konstan MW, Doring G, Lands L, et al. Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease (abstract). Pediatr Pulmol 2005;40(S28):125.
94. Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366:463-71.
95. Block JK, Vandemheen KL, Tullis E, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax 2006;61:969-74.
96. Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001;164:2102-6.
97. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001;163:43-8.
98. Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004;3:93-8.
99. De Soyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001;358:1780-1.
100. Jones AM, Dodd ME, Govan JR, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004;59:948-51.
101. Ledson MJ, Walshaw MJ. Burkholderia infection and survival in CF. Thorax 2005;60:439.
102. Lewin LO, Byard PJ, Davis PB. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990;43:125-31.
103. Nelson JW, Doherty CJ, Brown PH, et al. Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet 1991;338:1525.
104. Malfroot A, Adam G, Ciofu O, et al. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005;4:77-87.
105. Adlard P, Bryett K. Influenza immunization in children with cystic fibrosis. J Int Med Res 1987;15:344-51.
106. Gruber WC, Campbell PW, Thompson JM, et al. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study. J Infect Dis 1994;169:241-7.
107. King JC Jr, Gross PA, Denning CR, et al. Comparison of live and inactivated influenza vaccine in high risk children. Vaccine 1987;5:234-8.
108. Schaad UB, Buhlmann U, Burger R, et al. Comparison of immunogenicity and safely of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 2000;44:1163-7.
109. Lahiri T, Waltz DA. Preimmunization anti-pneumococcal antibody levels are protective in a majority of patients with cystic fibrosis. Pediatrics 2001;108:E62.
110. Krauth C, Jalilvand N, Welte T, et al. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003;21:1001-24.
111. Pauly MV. The economics of cystic fibrosis. In: Lloyd-Still JD, eds. Textbook of cystic fibrosis. Boston, USA: Jolin Wright PSG Inc, 1983:465-76.
112. US Congress Office of Technology Assessment. Cystic fibrosis and DNA tests: implications of carrier screening. Washington, USA: US Government Printing Office, 1992.
113. Wildhagen MF, Verheij JB, Verzijl JG, et al. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1. Thorax 1996;51:298-301.
114. Wildhagen MF, Verheij JB, Verzijl JG, et al. The nonhospital costs of care of patients with CF in The Netherlands: results of a questionnaire. Eur Respir J 1996;9:2215-9.
115. Abbott J, Dodd M, Bilton D, et al. Treatment compliance in adults with cystic fibrosis. Thorax 1994;49:115-20.
116. Abbott J, Dodd M, Webb AK. Health perceptions and treatment adherence in adults with cystic fibrosis. Thorax 1996;51:1233-8.
117. Conway SP, Pond MN, Hamnett T, et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996;51:29-33.
118. Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41:656-65.
119. Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv 2005;2:377-90.
120. de Boer AH, Le Brun PP, van der Woude HG, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm 2002;54:17-24.
121. Le Brun PP, de Boer AH, Mannes GP, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: Part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002;54:25-32.
122. Charlton B, Lassig A. CF-201 Study Investigators. Inhaled dry powder mannitol (bronchitol) improves FEV1 in cystic fibrosis (abstract). J Cyst Fibros 2006;5(suppl 1):S11.
123. Reilly BM. The essence of EBM. BMJ 2004;329:991-2.
124. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2.
125. Elborn JS, Prescott RJ, Stack BH, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000;55:355-8.